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ABSTRACT
Transcription factors (TFs) act withinwider regulatory networks to control
cell identity and fate. Numerous TFs, including Scl (Tal1) and PU.1
(Spi1), are known regulators of developmental and adult
haematopoiesis, but how they act within wider TF networks is still
poorly understood. Transcription activator-like effectors (TALEs) are a
novelclassofgenetic toolbasedon themodularDNA-bindingdomainsof
Xanthomonas TAL proteins, which enable DNA sequence-specific
targeting and the manipulation of endogenous gene expression. Here,
we report TALEs engineered to target the PU.1-14kb and Scl+40kb
transcriptional enhancers as efficient new tools to perturb the expression
of these key haematopoietic TFs. We confirmed the efficiency of these
TALEs at the single-cell level using high-throughput RT-qPCR, which
also allowed us to assess the consequences of bothPU.1 activation and
repressiononwider TFnetworks during developmental haematopoiesis.
Combined with comprehensive cellular assays, these experiments
uncovered novel roles for PU.1 during early haematopoietic
specification. Finally, transgenic mouse studies confirmed that the
PU.1-14kb element is active at sites of definitive haematopoiesis in vivo
andPU.1 is detectable in haemogenicendotheliumandearly committing
blood cells.We therefore establish TALEs as powerful new tools to study
the functionality of transcriptional networks that control developmental
processes such as early haematopoiesis.
KEY WORDS: Haematopoiesis, Transcription activator-like
effectors, Regulatory networks, PU.1
INTRODUCTION
Transcriptions factors (TFs) are key regulators of cell identity and fate.
Cell type-specific transcriptional regulation is thought to largely occur
by TF binding to distal cis-regulatory elements (Heinz et al., 2010).
The haematopoietic system provides a well-studied model of
mammalian tissue development, in which numerous key TFs have
been described [reviewed by Wilkinson and Gottgens (2013)],
including Scl (Tal1) and PU.1 (Spi1). The identification of cis-
regulatory elements that regulate the expression of such TFs has begun
to reveal TF circuits that suggest the existence of highly interconnected
TF regulatory networks active in the haematopoietic system (Pimanda
and Gottgens, 2010; Schutte et al., 2012).
Two well-studied examples of such haematopoietic cis-
regulatory elements are the PU.1-14kb (Rosenbauer et al., 2004;
Okuno et al., 2005; Huang et al., 2008; Staber et al., 2013) and Scl
+40kb (Delabesse et al., 2005; Ogilvy et al., 2007; Ferreira et al.,
2013). The PU.1-14kb plays a key role in PU.1 expression in
haematopoietic stem/progenitor cells (HSPCs) and mature
haematopoietic cell types; its deletion results in an 80% loss of
PU.1 gene expression and acute myeloid leukaemia (AML) in mice
(Rosenbauer et al., 2004), while mutation of an (autoregulatory) Ets
site within the PU.1-14kb causes a 66% reduction in PU.1 gene
expression, which leads to haematopoietic stem cell exhaustion
(Staber et al., 2013). Although the Scl+40kb element is active
during haematopoietic emergence, its deletion causes only a mild
erythroid phenotype (Ferreira et al., 2013). The Scl+40kb element is
additionally thought to regulate expression of the 3′ flanking gene,
Map17 (Pdzk1ip1) (Tijssen et al., 2011; Ferreira et al., 2013).
Recent technological advances in microfluidic technology have
led to the development of robust protocols for high-throughput
quantification of gene expression in single cells (Guo et al., 2010).
One of the earliest studies reporting microfluidics-based single-cell
gene expression highlighted the potential for heterogeneity of
knockdown efficiency within single cells following siRNA-
mediated gene silencing (Toriello et al., 2008). However, the
ability to accurately assess gene expression in single cells following
conventional perturbations, such as retroviral overexpression or
shRNA-mediated knockdown, has been limited because the former
commonly yields unphysiologically high expression levels with no
means to distinguish between the endogenous and ectopically
expressed gene, whereas the latter acts post-transcriptionally and
can therefore inhibit protein production without affecting transcript
abundance. To realise the full potential of analysing perturbation
phenotypes by single-cell gene expression profiling, more
physiological means to tune gene expression levels are therefore
required.
Transcription activator-like effectors (TALEs) are a novel class of
TFs identified in the bacterial plant pathogen Xanthomonas, where
they are secreted as virulence factors to modulate gene expression of
the host plant (Boch and Bonas, 2010). TALEs have a uniqueReceived 25 July 2014; Accepted 18 August 2014
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modular DNA-binding domain consisting of 33-35 amino acid
repeats, each of which binds a single nucleotide with base
recognition specificity (Boch et al., 2009). TALEs fused to
transcriptional effector domains have been shown to modulate
endogenous gene expression (Zhang et al., 2011; Cong et al., 2012;
Gao et al., 2013).
Here, we present the use of TALEs (fused to transcriptional
effector domains) designed to target conserved regions within
haematopoietic TF cis-regulatory elements as an efficient tool to
regulate target gene expression. We validated TALEs targeting the
PU.1-14kb and Scl+40kb elements and further assessed the
phenotypic effect of modulating the activity of these enhancers on
embryoid body (EB) haematopoiesis. We go on to highlight the
combination of TALE-mediated endogenous gene expression
perturbations with single-cell gene expression studies as a
powerful approach to investigate TF regulatory networks. Using
these methods in combination with transgenic embryo analysis, we
uncover a novel role for PU.1 expression, mediated via PU.1-14kb,
in haematopoietic specification during development.
RESULTS
Design and validation of TALEs targeting conserved regions
within haematopoietic enhancers
We identified regions within the Scl+40kb and PU.1-14kb elements
that were perfectly conserved between human and mouse. TALEs
were designed to match these regions and nowhere else in either
genome (Fig. 1A-C). TALEs were initially assembled fused to the
VP64 (transcriptional activator) domain (Beerli et al., 1998) and an
mCherry fluorescent reporter via a 2A peptide (Fig. 1A). TALE
constructs were cloned into piggyBac transposon-based plasmids
(Wang et al., 2008) for efficient stable genomic integration and
under the control of a tetracycline-responsive promoter (TetR) to
provide inducible [with doxycycline (dox)] expression (Fig. 1A).
We initially validated TALE-VP64 proteins in both human and
mouse systems (Fig. 1D). In human K562 cells, the TALE-VP64
targeting Scl+40kb (T-VP64-Scl+40) upregulated SCL expression
∼4-fold but had little effect on MAP17 expression (Fig. 1E). By
contrast, in mouse 416B cells T-VP64-Scl+40 upregulated Map17
expression ∼22-fold but had little effect on Scl expression (Fig. 1E).
In both the human K562 and mouse 416B cells, expression of the
TALE-VP64 targeting PU.1-14kb (T-VP64-PU.1-14) upregulated
PU.1 expression 3- to 4-fold and SLC39A13/Slc39a13 expression
∼2-fold (Fig. 1F).
Modest (1.5- to 8.5-fold) increases in histone H3 lysine 27
acetylation (H3K27Ac), an epigenetic modification associated with
active regions of chromatin (Creyghton et al., 2010), were also seen
in 416B cells at the promoters of TALE-VP64 target genes,
consistent with increased transcription (supplementary material
Fig. S1A,B). H3K27Ac was also enriched 3.8-fold at Scl+40kb
when the TALE-VP64 targeting this enhancer was expressed
(supplementary material Fig. S1A). However, a 50% reduction in
H3K27Ac was seen at PU.1-14kb when the TALE-VP64 targeting
this enhancer was expressed (supplementary material Fig. S1B),
perhaps due to nucleosome displacement caused by TALE-VP64
and co-factor DNA binding. In mouse embryonic stem cells
(mESCs), in which these enhancers are not active (as determined by
H3K27Ac ChIP-seq enrichment; data not shown) and target genes
are weakly expressed, TALE-VP64 did not upregulate gene
expression (supplementary material Fig. S1C,D).
To determine the specificity of these TALEs, we further
determined expression changes to genes within ∼100 kb of the
target regions (supplementary material Fig. S1E-H). Less than 1.7-
fold increases in expression were seen in K562, 416B and mESCs.
Reduced expression in some genes (such as Stil in 416B cells
expressing T-VP64-Scl+40) was identified, perhaps due to
transcription factory reallocation (Papantonis and Cook, 2013).
Additionally, we confirmed by chromatin immunoprecipitation
(ChIP) that TALEs bind to their target regions. By ChIP-qPCR,
enrichments of 15- to 17-fold were seen at target locations
(Fig. 1G,H). To further assess TALE binding specificity genome-
wide, we sequenced the HA-T-VP64-PU.1-14 and 416B control
HA antibody ChIP samples. The number of regions across the
entire genome that showed enrichment was very small and
comparable between the 416B control and HA-T-VP64-PU.1-14
samples, underlining the high specificity afforded by TAL-
mediated targeting reported by others (Mali et al., 2013).
Importantly, a clear peak at the PU.1-14kb element could be
identified in the HA-T-VP64-PU.1-14 sample, but not in the control
(supplementary material Fig. S1I). Manual assessment of
enrichment at regions containing similar DNA sequences to the
HA-T-VP64-PU.1-14 target sequence did not identify strong off-
target binding, and no other binding events occurred within a 15 Mb
window around PU.1-14kb (supplementary material Fig. S1I).
We next assessed the ability of TALEs to regulate target gene
expression during development using the mouse EB differentiation
system, which has been validated as a useful and tractable in vitro
model of embryonic haematopoiesis (Keller et al., 1993). We
transfected the mESC line Ainv18 (Kyba et al., 2002), which
constitutively expresses rtTA from the Rosa26 locus, and expanded
stably integrated clones that displayed inducible mCherry expression
(data not shown). The data described below are representative of
multiple clones tested for each TALE construct. We differentiated
TALE-containing ESC lines, induced TALE expression by addition
of dox at day 4 (just prior to definitive haematopoiesis in this system)
and assessed phenotypic effects after a further 48 h of culture, relative
to a culture without dox treatment (Fig. 2A). Initial flow cytometric
analysis of the day 6EBs confirmed puremCherry+ populations in the
dox cultures (Fig. 2A). Following this protocol, Scl expression was
upregulated ∼1.9-fold in cells induced to express T-VP64-Scl+40,
andMap17 expression was upregulated over 3-fold (Fig. 2B). PU.1
expression was upregulated over 4-fold by T-VP64-PU.1-14, with
no significant change in Slc39a13 expression (Fig. 2B). We
additionally generated ESCs containing a PU.1-14kb-targeting
TALE for PU.1 repression by swapping the VP64 activation domain
for the KRAB repressor domain (T-KRAB-PU.1-14). Following the
same differentiation protocol as above, we observed efficient
repression of PU.1 by the TALE-KRAB, with expression reduced
by over 50% (Fig. 2B). Slc39a13 was unaffected by TALE
expression, suggesting that, at least in this developmental context,
PU.1-14kb activity is specific to PU.1.
Transient expression of a PU.1 enhancer-targeting TALE
alters EB haematopoiesis
We next assessed the phenotypic effect of TALE-mediated
modulation of gene expression by haematopoietic colony forming
assays using day 6 EB cells (supplementary material Fig. S2A).
TALE-VP64-mediated PU.1 upregulation resulted in a significant
loss of colony forming ability in day 6 EBs (Fig. 2C). By contrast,
TALE-KRAB-mediated PU.1 repression caused a doubling in
myeloid (CFU-GM/G) and mixed (CFU-Mix) colony numbers
(Fig. 2C), although this was not statistically significant. The colony
potential of day 6 EBs was largely unaffected by expressing
T-VP64-Scl+40, except for a slight (but not significant) increase in
BFUe frequency (Fig. 2C).
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To ensure that TALE-VP64 expression alone was not affecting
CFU frequency, we assessed ESC lines carrying a non-functional
TALE-VP64 [generated previously (Gao et al., 2013)], which did
not affect CFU frequency (supplementary material Fig. S2B). To
correlate the changes in haematopoietic progenitors/CFUs with
changes in the cellular composition of the day 6 EBs, we analysed
day 6 EBs by flow cytometry. Consistent with the modest effects in
colony forming assays, expression of T-VP64-Scl+40 minimally
affected haematopoietic cell populations present in day 6 EBs
(supplementary material Fig. S2C). Expression of TALEs targeting
the PU.1-14kb partially, but not significantly, reduced the total cell
numbers recovered (supplementary material Fig. S2D). However,
this was not due to increased apoptosis, as assessed by Annexin V
and DAPI staining of day 6 EBs (supplementary material Fig. S2D).
Although TALE-VP64-mediated upregulation of PU.1 caused an
increase in the relative size of the CD41+ population (Fig. 2D;
Fig. 1. Experimental approach and validation. (A) Structure of the TALE-expressing piggyBac construct. TALE cDNA consists of the TALE sequence followed
by a nuclear localisation domain (NLS), a VP64 domain, 2A (peptide sequence cleaved after translation) and mCherry fluorescent protein. TALE cDNA was
cloned downstream of a tetracycline-responsive promoter (TetR), and within piggyBac long terminal repeats (LTRs) for stable transposase-mediated genomic
integration. The DNA-binding domain (DBD) within the TALE sequence consists of twenty monomers. Monomers contain two hypervariable amino acids that
determine nucleotide-binding specificity: NN, NI, NG or HD. (B,C) Schematics of themouseScl (Tal1) (B) andPU.1 (Spi1) (C) genomic loci, with theScl+40kb and
PU.1-14kb elements highlighted in green. TALE target sites within conserved (between human and mouse) sequences are highlighted in red. (D) Experimental
approach to express TALEs in cell lines. K562 and 416B cells were co-transfected with the TALE-expressing piggyBac (TALE-PB) from A, a constitutively
expressing rtTA piggyBac vector (pCAG-rtTA-PB) and a piggyBac transposase, to create inducible TALE-expressing cells. (E) Effect of expressing TALE-VP64
targeting Scl+40kb (T-VP64-Scl+40) in human K562 (left) and mouse 416B (right) cells on neighbouring gene expression. T-VP64-Scl+40 was expressed for
48 h by addition of doxycycline (dox) and gene expression inmCherry+ cells was determined relative tomCherry− control cells. Error bars indicate s.d. of technical
triplicates, and are representative of two biological replicates. (F) As in E, but for TALE-VP64 targeting PU.1-14kb (T-VP64-PU.1-14). (G) ChIP approach for
TALE-VP64 proteins in H. An HA affinity tag was inserted at the N-terminus of the TALE-VP64 (HA-T-VP64); 416B cells were co-transfected as in D, sorted and
ChIP performed 48 h after dox addition. (H) ChIP-qPCR enrichment of HA-tagged TALE-VP64 (HA-T-VP64) relative to IgG in HA-T-VP64-Scl+40 (pink), HA-T-
VP64-PU.1-14 (red) and untransfected 416B control (green) cells at Scl+40kb, PU.1-14kb and a control region on chromosome 1 (Chr1). Error bars indicate s.d.
of technical triplicates from one biological experiment.
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Fig. 2. Transient TALE expression affects haematopoietic cell fate decisions. (A) Experimental approach using Ainv18 ESC differentiation to study
TALE-mediated gene expression perturbations in haematopoiesis. Mouse Ainv18 ESCs constitutively expressing rtTA from the Rosa26 locus (pR26-rtTA) were
co-transfected with the inducible TALE-PB construct and transposase. Targeted ESCs were differentiated into embryoid bodies (EBs), and TALE expression
induced at day 4 by addition of dox. Changes in gene expression, colony potential and surface marker phenotype were analysed at day 6 in the +dox EBs as
compared with−dox controls. (B) Gene expression changes in day 6 EBs after induction of T-VP64-Scl+40 (left), T-VP64-PU.1-14 (middle) and T-KRAB-PU.1-14
(right). Error bars indicate s.e.m. of three biological replicates. (C) Representative haematopoietic colony numbers from 1×105 day 6 EB cells (colour scheme as in
B). Colonies were grown inmethylcellulose supplemented with SCF, IL-3, IL-6 and Epo. See supplementary material Fig. S2A for images of representative colony
forming units (CFUs) scored. Error bars indicate s.d. of technical triplicates. *P<0.05, **P<0.01 (Student’s t-test), from three biological replicates. (D) Flow
cytometry plots of day 6 EB cells showing Flk1 versus CD41 (top) and VEcad versus CD41 (bottom). Representative staining patterns are shown for T-VP64-
PU.1-14 (left) and T-KRAB-PU.1-14 (right). The distribution of cells within quadrants/gates is shown by percentage. (E) Relative number of day 4 Flk1+EB-derived
colonies containing CD41+ haematopoietic cells, grown on OP9 stromal cells for 84 h (dox added after 36 h). See supplementary material Fig. S2G for
representative image of scored colony. Error bars indicate s.e.m. from biological triplicates. *P<0.01 (Student’s t-test), from three biological replicates. (F) Average
numbers of haematopoietic colonies from 1×105 day 6 EB T-KRAB-PU.1-14 cells plated onto confluent OP9 stromal cells for 24 h before CFU assay initiated by
addition of methylcellulose supplemented with SCF, IL-3, IL-6 and Epo. Colour scheme as in B. Error bars indicate s.d. of three biological replicates. *P<0.05
(Student’s t-test), from three biological replicates.
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supplementary material Fig. S2E), when combined with total cell
numbers recovered from the EBs this did not result in a significant
increase in the absolute number of CD41+ cells (supplementary
material Fig. S2F). Interestingly, TALE-VP64-mediated PU.1
expression caused a loss of the Flk1+ (mesoderm) population
(supplementary material Fig. S2E,F), and significantly increased the
CD41+ VE-cadherin (VEcad)+ (committing haemogenic endothelial)
population (Fig. 2D; supplementary material Fig. S2F). Additionally,
TALE-VP64-mediatedPU.1 upregulation caused a loss of the CD41+
cKithi (‘early definitive haematopoietic progenitor’) population,
which might help explain the loss of colony forming potential
described above (Fig. 2C,D). Combined with the CFU assays, these
data suggested that PU.1 upregulationmight push differentiating cells
towards a haematopoietic fate but then inhibits proliferation of the
resultingblood cells.Consistentwith this hypothesis, TALE-mediated
PU.1 induction modestly increased (1.5-fold) day 4 EB-derived
colonies containing budding CD41+ haematopoietic cells (Fig. 2E;
supplementarymaterial Fig. S2G),whereasPU.1 repressionmodestly
reduced their frequency.
By contrast, the major change caused by downregulation of PU.1
by T-KRAB-PU.1-14 was an almost complete loss of the CD45+
(Ptprc+) population (committed definitive haematopoietic cells;
supplementary material Fig. S2E), which led us to speculate that the
delayed haematopoiesis caused by PU.1 repression might be
masking an increase in haematopoietic CFU frequency. To test
this further, we allowed day 6 EB cells to mature on OP9 stromal
cells for 24 h before assessing CFU frequency (Fig. 2F). This led to
a significant 3-fold and 9-fold increase in BFUe and CFU-Mix
colonies, respectively, which is consistent with published data
suggesting that PU.1 expression restricts haematopoietic cells to a
myeloid fate (Mak et al., 2011).
Combined, these data suggest that upregulation of PU.1 drives
haematopoietic commitment, but causes loss of proliferative
ability within the haematopoietic population, whereas temporary
downregulation of PU.1 inhibits the maturation and differentiation
of early haematopoietic cells.
Single-cell gene expression analysis of TALE-mediated PU.1
perturbation
Having determined the phenotypic effects of TALE-mediated PU.1
expression perturbations, we next asked what effects PU.1
modulation might have on TF regulatory networks. We assessed
the effect of T-VP64-PU.1-14 induction on the expression of 44
haematopoietic, mesodermal and endothelial TFs and surface
markers as well as four control housekeeping genes in single day-
6 EB VEcad+ cells using the Fluidigm Biomark platform. At this
time point, VEcad expression marks endothelium and haemogenic
endothelium, which were not expected to express robust levels of
PU.1. To provide an internal control, we differentiated a chimeric
mixture of wild-type (WT) and TALE-inducible ESCs, and sorted
VEcad+ cells from mCherry− and mCherry+ populations at day 6
(48 h after dox addition; Fig. 3A). We assessed the expression of
all 48 genes in 160 single cells for each population, which, after
quality control, resulted in expression data for 136 and 147 cells,
respectively.
PU.1was only expressed in 33% (45 of 136) of mCherry−VEcad+
cells (Fig. 3B). By contrast, TALE-VP64 efficiently induced PU.1
expression in 84% (124 of 147) of the mCherry+ VEcad+ cells.
Moreover,PU.1-expressing cells in themCherry+ VEcad+ population
tended to expressPU.1 at a higher level than thePU.1-expressing cells
in the mCherry− VEcad+ population (an average of 3.3 ΔCt higher,
relative to Polr2a and Ubc expression; Fig. 3B). This demonstrates
that T-VP64-PU.1-14 can induce gene expression efficiently (but not
with complete efficiency), and that the distribution ofPU.1 expression
levels within PU.1-expressing cells is altered, with a much larger
proportion of individual cells expressing high levels of PU.1. Single-
cell expression analysis therefore reveals both qualitative (a shift
towardsmore cells expressing) and quantitative (a shift towards higher
per-cell expression levels) consequences of TALE-mediated
activation of PU.1.
Importantly, TALE-induced PU.1 expression was associated
with consistent changes in the expression of other genes. mCherry+
cells expressed higher levels of several haematopoietic genes,
including Csf1r, Gata3, Gfi1b, Runx1 and Etv6 (Tel) (Fig. 3B).
Interestingly, mCherry+ cells also express lower levels of several
genes thought to be important for mesoderm or endothelium,
including Ets1, Etv2, Flk1 (Kdr), Notch1, Sox17 and VEcad (Cdh5)
(Fig. 3B). Moreover, gene expression changes for Flk1, CD41
(Itga2b) and Kit correlated well with the expression of these surface
markers as assessed by flow cytometry (Fig. 2D and Fig. 3B;
supplementary material Figs S2 and S3). As Kit encodes the
receptor for the pro-proliferative cytokine stem cell factor (Scf;
Kitl), its downregulation at the transcriptional level and cell surface
might partially explain the loss of proliferative ability in T-VP64-
PU.1-14-expressing day 6 EB cells (Fig. 2E).
Pairwise all-against-all comparisons of the expression of the 44TFs
and surface proteins across all 283 single cells were performed by
calculating Spearman rank correlation coefficients, which were
displayed using a heatmap to illustrate both positive and negative
correlations between pairs of genes. This identified two positively
correlated gene clusters: a haematopoietic gene cluster (including
PU.1) and amesodermal/endothelial gene cluster (Fig. 3C). Although
genes from both clusters can be co-expressed in single cells (Fig. 3D),
genes from the haematopoietic cluster predominantly showed
negative correlation to genes from the endothelial cluster (Fig. 3C),
suggesting an antagonism between these regulatory networks.
Pairwise analysis and hierarchical clustering of cells based on their
gene expression signatures largely separated the mCherry− and
mCherry+ cells within the VEcad+ population (Fig. 3D). As expected,
it was within the mCherry+ population that the positively correlated
cluster of haematopoietic genes was more frequently activated.
PU.1 can promote haematopoietic commitment of
haemogenic endothelial precursors
The data described above suggest that precocious PU.1 expression in
haematopoietic precursors can drive haematopoietic commitment
through the activation of a TF network. To investigate this further,
we performed additional single-cell gene expression analyses for
the CD41+ cKithi population from WT and T-KRAB-PU.1-14
differentiated ESCs. As above, 160 mCherry+ and mCherry− cells
were sorted from day 6 EBs, from which 142 and 141 single cells,
respectively, passed quality control. Within the CD41+ cKithi
mCherry− (WT Ainv18) population, over 90% expressed PU.1 (132
of 141), and clearly had acquired a committed haematopoietic gene
expression pattern (including Runx1, Myb, Ikaros) with only a few
cells expressing mesoderm/endothelium-associated genes (e.g. Sox7,
Sox17, Etv2) (Fig. 4A; supplementary material Fig. S4). By contrast,
less than 60% (85 of 142) of the CD41+ cKithi mCherry+ (TALE-
KRAB-PU.1-14) cells expresseddetectablePU.1 transcript, andPU.1
was expressed at lower levels in those that did (an average of 2.8 ΔCt
lower; Fig. 4A), demonstrating that TALE-KRAB efficiently
repressed PU.1 expression in CD41+ cKithi cells. The expression of
Csf1r, a known downstream target of PU.1, is tightly correlated with
PU.1 expression and Csf1r is not expressed in cells lacking PU.1
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Fig. 3. Single-cell analysis of TALE-mediated PU.1 expression in haematopoietic precursors. (A) Strategy for single-cell gene expression analysis of
TALE-mediated perturbations. Wild-type (WT) Ainv18 and T-VP64-PU.1-14-targeted ESCs were passaged once as a 1:1 mix before EB formation. Dox
was added at day 4 and EBs disaggregated at day 6. Single VEcad+ cells (mCherry+ and mCherry− sorted as T-VP64-PU.1-14-expressing and WT,
respectively) were sorted into lysis buffer. Single-tube reverse transcription and targeted pre-amplification were undertaken, followed by multiplexed qPCR
gene expression analysis using the Fluidigm Biomark platform. (B) Density plots of gene expression in day 6 EB VEcad+ mCherry− (136 WT Ainv18; cyan)
and VEcad+ mCherry+ (147 T-VP64-PU.1-14 expressing; red) cells. The density indicates the fraction of cells at each expression level, relative to
housekeeping genes (Polr2a and Ubc). Cells with non-detected gene expression were set to –12. See supplementary material Fig. S3 for density plots for
all 48 genes analysed in these two populations. (C) Hierarchical clustering of Spearman rank correlations between all pairs of genes (excluding
housekeepers) from all 283 VEcad+ cells (red, positive correlation; blue, negative correlation). (D) Hierarchical clustering of the 283 VEcad+ cells according
to gene expression, with genes ordered according to C (dark red, highly expressed; grey, non-expressed). Top bar indicates cell type: cyan, mCherry−; red,
mCherry+.
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Fig. 4. TALE-mediated expression perturbations suggest transcriptional interactions during blood specification. (A) Density plots of gene expression
in day 6 EB CD41+ cKithi (CD41cKit) mCherry− (141 WT Ainv18; orange) and CD41cKit mCherry+ (142 Ainv18 expressing T-KRAB-PU.1-14; purple) cells.
The density indicates the fraction of cells at each expression level, relative to housekeeping genes (Polr2a and Ubc). Cells with non-detected gene expression
were set to –12. See supplementary material Fig. S4 for density plots for all 48 genes analysed in these two populations. (B) Hierarchical clustering of Spearman
rank correlations between all pairs of genes (excluding housekeepers) using gene expression data from all 566 cells (VEcad+ and CD41cKit). (C) Principal
component analysis (PCA) of the 566 VEcad+ and CD41cKit cells, in the first and second components, from the expression of all 44 genes (excluding the four
housekeeping genes). (D) Principal component loadings indicate the extent to which each gene contributes to the separation of cells along each component in
C. (E) Current model of definitive haematopoietic specification from Flk1+ mesoderm through a haemogenic endothelial precursor to a haematopoietic stem/
progenitor that can differentiate into lymphoid, myeloid or erythroid lineages. (F) Endothelial potential of TALE-expressing VEcad+ cells, as a percentage of –dox
control cells. *P<0.01 (Student’s t-test), from three biological replicates.
4024











(Fig. 4A). Other genes affected by repression ofPU.1 in CD41+ cKithi
cells included the downregulation of Ikaros and Lyl1, as well as the
upregulation of Erg, Gata2 andMyb or an increase in the fraction of
cells expressing the respective genes (Fig. 4A).
Having generated a total of 566 single-cell expression profiles
from the TALE-VP64 and TALE-KRAB perturbation experiments,
we next combined all the expression data to explore the potential of
this substantial dataset for the identification of possible regulatory
relationships. Pairwise all-against-all comparisons were performed
as before by calculating Spearman rank correlation coefficients
(Fig. 4B). This analysis placed PU.1 next to a cluster of
haematopoietic genes containing, among others, Myb, Runx1 and
Ikaros. A second cluster of strongly correlating genes consisted of
endothelial genes (e.g. Sox7, VEcad, Pecam1). Gata2 was adjacent
to a third and somewhat smaller cluster consisting of erythroid genes
such as Gata1, Epb4.2 and globin genes. Of note, PU.1 showed
negative correlation with Gata2, as expected from the results in
Fig. 4A, but not with core erythroid genes such as Gata1.
Additionally, we observed negative correlation of PU.1 with
many genes within the ‘endothelial’ cluster, suggesting that PU.1
might antagonise endothelial fate.
To further assess possible effects of PU.1 expression
perturbations on the entire multi-dimensional gene expression
dataset from all 566 cells, we performed principal component
analysis (PCA). PCA separated the two mCherry− populations
(VEcad+ and CD41+ cKithi) into distinct groups across principal
component 1 (PC1), consistent with the notion of two
developmentally distinct populations (Fig. 4C). This separation is
driven by the expression of endothelial genes in the VEcad+
population (including VEcad, Sox17, Sox7) and haematopoietic TFs
in the CD41+ cKithi population (including Runx1, Myb, Gfi1b,
Ikaros and PU.1) (Fig. 4D). The CD41+ cKithi population is
resolved into two populations by PC2, by expression of myeloid
genes (including PU.1 and Csf1r) and erythroid genes (including
Hbb-bh1, Gata1, Epor), suggesting that the CD41+ cKithi
population contains myeloid- and erythroid-biased CD41+ cKithi
progenitor cells. PCA of our dataset therefore provided good
resolution of early developmental populations based on current
models of developmental haematopoietic specification [Fig. 4E,
based on Medvinsky et al. (2011)]. Interestingly, T-VP64-PU.1-14
mCherry+ VEcad+ cells bridge the separation between the control
VEcad+ and CD41+ cKithi populations (Fig. 4C), consistent with the
notion that PU.1 expression pushes VEcad+ cells to haematopoietic
commitment but is unable to drive the transition completely. By
contrast, the separation of the T-KRAB-PU.1-14 mCherry+ CD41+
cKithi population from the mCherry− CD41+ cKithi population is
less striking, although more PU.1 repressed cells are closer to the
VEcad+ population and none form part of the most distant group of
cells in the top right-hand part of the plot (Fig. 4C), consistent with
the block observed in haematopoietic maturation.
Both the pairwise correlation analysis and PCA suggested that
PU.1 expression contributes to a haematopoietic fate in VEcad+
cells. We therefore assessed the effect of PU.1 perturbation on the
endothelial potential of the day 6 VEcad+ cells. TALE-VP64-
mediated PU.1 activation inhibited endothelial colony formation,
whereas PU.1 repression did not (Fig. 4F; supplementary material
Fig. S5). Combined, these data suggest that activation of PU.1
expression during developmental haematopoiesis plays a role in
driving a haematopoietic rather than endothelial transcriptional
programme, and that activation of PU.1 expression in haemogenic
endothelium might be an important molecular decision in
haematopoietic commitment.
Such a large single-cell gene expression dataset presented the
opportunity to investigate underlying TF network interactions
active during the endothelial-to-haematopoietic transition (EHT)
using partial correlation analysis. This analysis identifies network
interactions (edges) by detecting irreducible statistical dependencies
between TFs that cannot be otherwise explained by other statistical
dependencies within the network (see supplementary material
Tables S1 and S2). To visualise the results, we plotted the 34
network edges between the TF nodes with highly significant
correlations (P<0.0001; Fig. 5). Although this method of analysis
provides positive/negative correlation information, directionality
cannot be inferred. Most TF interactions were positive and formed a
highly interconnected network, which could be important in network
stabilisation. Two types of negative correlations were observed: (1)
between haematopoietic genes and endothelial genes, including
Runx1 and Sox17; and (2) between haematopoietic lineage-specific
genes, including Nfe2 and Gata3. Such TF antagonisms might be
important switches in cell fate commitment.
Fig. 5. Partial correlation analysis identifies a
highly interconnected TF network that is active
during the EHT. (A) Method used to build the TF
network model in B. (B) TF network model showing
highly statistically significant interactions (P<0.0001)
as connections (edges) between TFs (nodes).
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ThePU.1-14kb enhancer is active in themid-gestation dorsal
aorta in vivo
The above data suggest that PU.1 plays a role in driving endothelial
cells to a haematopoietic fate. Although PU.1 expression at sites of
embryonic definitive haematopoiesis has been reported (Huang
et al., 2008; Swiers et al., 2013), very little is known about its
transcriptional regulation during developmental haematopoiesis in
vivo. We therefore generated E11.5 transient transgenic mouse
embryos carrying lacZ reporter gene constructs. The PU.1 promoter
alone (PU.1prom/LacZ) was unable to drive lacZ expression
(Fig. 6A-C), suggesting that distal enhancers govern PU.1
expression at this developmental stage. To determine the activity
of the PU.1-14kb enhancer, we initially generated transgenic mouse
embryos carrying the enhancer downstream of a lacZ reporter driven
by the SV40 minimal promoter (SV40prom/LacZ/PU.1-14;
Fig. 6B). In E11.5 mouse embryos, PU.1-14kb drove lacZ
expression in cell clusters budding from the dorsal aorta (DA), a
site of definitive haematopoiesis (Fig. 6C). lacZ expression was also
seen in a minority of endothelial cells within the DA and rare
circulating blood cells (Fig. 6C). These data demonstrate that PU.1-
14kb is activated in vivo at embryonic sites of the EHT. By
comparison, previous analysis of Scl+40kb failed to identify
activity in the endothelium or budding clusters of the DA at
E11.5, although primitive blood cells and HSPCs residing in the
foetal liver later in development were lacZ+ (Ogilvy et al., 2007).
Toconfirm theabilityof thePU.1-14kb enhancer to drive expression
from the PU.1 promoter, we also generated transient transgenic
embryos carrying PU.1-14kb downstream of the PU.1 promoter
driving lacZ (PU.1prom/LacZ/PU.1-14; Fig. 6B). Embryos analysed
at E11.5 also showed expression in cell clusters budding from the DA
and endothelial patches of the DA, but expression in circulating cells
was less obvious than with SV40prom/LacZ/PU.1-14 (Fig. 6C). As a
control, we generated transgenic embryos carrying a different putative
PU.1 cis-regulatory element, PU.1-18kb (Chou et al., 2009; Zarnegar
and Rothenberg, 2012), downstream of lacZ driven by the SV40
minimal promoter (SV40/LacZ/PU.1-18; Fig. 6A,B). E11.5 SV40/
LacZ/PU.1-18 embryos failed to display staining in the DA or
circulating blood (Fig. 6C), although non-haematopoietic lacZ
expression was detected (such as in the neural tube). We conclude
that PU.1-14kb activates the PU.1 promoter during the EHT, although
other cis-regulatory elements are likely to be involved in regulating
PU.1 expression during this process as PU.1-14kb is unable to
confer physiological PU.1 expression in PU.1−/− mice (Leddin
et al., 2011).
PU.1 is detectable within endothelium of the aorta-gonad-
mesonephros region and vitelline and umbilical arteries,
and is upregulated during the EHT in vivo
Single-cell gene expression analysis has recently been used to study
the EHT in the developing embryo (Swiers et al., 2013) using a
Runx1+23kb enhancer-reporter (Runx1+23GFP) transgenic mouse
line. Combined with surface markers, this reporter line allows
further resolution of the cell types involved in the EHT:
endothelium (VEcad+ Runx1+23GFP− Ter119− CD41− CD45−),
haemogenic endothelium (VEcad+ Runx1+23GFP+ Ter119−
CD41− CD45−), committing HSPCs (VEcad+ Runx1+23GFP+
Ter119− CD41+ CD45−) and mature HSPCs (VEcad+ Runx1
+23GFP+ Ter119− CD41+ CD45+). We re-analysed this dataset to
specifically study PU.1 expression during haematopoietic
commitment in the aorta-gonad-mesonephros region and vitelline
and umbilical arteries (AGM+VUA) from E10.5 embryos
(Fig. 7A). As controls, we also re-analysed gene expression for
Fli1 (a TF expressed in endothelium and blood) and Myb
(a haematopoietic TF). Low expression of PU.1 was detectable in
∼5% of endothelium and ∼19% of haemogenic endothelium. Over
80% of early committing HSPCs expressed higher levels of PU.1,
and by the mature HSPC stage 97% of cells expressed robust levels
of PU.1. This expression profile was consistent at E8.5, E9.5 and
E11.5 (data not shown) (Swiers et al., 2013). These expression
dynamics were similar to those of the haematopoietic gene Myb,
Fig. 6. The PU.1-14kb element is
active at sites of mouse definitive
haematopoiesis in vivo. (A) Schematic of
the PU.1 locus highlighting the relevant
cis-regulatory elements. (B) Reporter
constructs used for transient transgenic
embryo generation. (C) Representative
lacZ+ whole-mount images and section
images (original magnification: 40×) of the
dorsal aorta of E11.5 transgenic embryos
carrying the reporters illustrated above in
B. Insets (original magnification: 100×)
show cell clusters budding from the ventral
side of the dorsal aorta. The number of
lacZ+ embryos/number of total PCR+
embryos analysed is indicated in each
whole-mount image.
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although it is interesting to note that, within the haemogenic
endothelium population, only 7% of cells expressed Myb, which is
lower than the 19% that were PU.1 expressing. By the committing
and mature HSPC states, Myb and PU.1 expression almost entirely
overlap. These data suggest that in vivo, PU.1 can be expressed in
the early haemogenic endothelial stages of the EHT, and is
upregulated during this haematopoietic cell fate commitment,
concomitant with CD41 surface expression.
Finally, to confirm this early expression of PU.1 at the protein
level during the EHT, we analysed PU.1 expression in the AGM
+VUA region of E10-10.5 PU.1-YFP knock-in homozygous mouse
embryos (Kirstetter et al., 2006) by flow cytometry (Fig. 7B). PU.1-
YFP was detectable in 0.6% of VEcad+ Ter119− CD41− CD45−
endothelium, 82% of VEcad+ Ter119− CD41+ CD45− committing
HPSCs and 97% of VEcad+ Ter119− CD41+ CD45+ mature HSPCs
(Fig. 7B,C; supplementary material Fig. S6). These results correlate
well with the in vivo and in vitro single-cell qPCR data (Fig. 3, Fig. 4
and Fig. 7A). Taken together, our results establish PU.1 and its
–14kb enhancer as likely key building blocks of the gene regulatory
network that drives early blood specification.
DISCUSSION
Here, we demonstrate a novel use of TALEs in combination with
single-cell gene expression profiling to investigate the
consequences of transcriptional perturbation of developmental
regulatory networks. High-throughput RT-qPCR coupled with
comprehensive cellular assays uncovered a previously unrecognised
role for PU.1 in the EHT. Transgenic mouse studies confirmed that
the PU.1-14kb enhancer is active at mid-gestation in the DA, where
the EHT occurs in vivo, and that PU.1 expression can be detected
from the endothelium stage of this process.
Our analysis of several hundred single cells with TALE induction
highlights the efficiency of TALE-mediated endogenous gene
expression perturbations at the single-cell level, which proved to be
comparable to alternative methods of perturbation such as siRNA
knockdown (Kouno et al., 2013), and provided more
physiologically relevant expression changes when comparing
upregulation of gene expression using TALE-VP64 proteins with
retroviral cDNA overexpression. Moreover, TALE-mediated
perturbation does not require a distinction between exogenous and
endogenous cDNAs, allows normal co- and post-transcriptional
processing to occur, and allows for detection by gene expression
primers that are located in untranslated regions (UTRs).
The CRISPR-Cas9 system has recently been adapted to modulate
gene expression by a similar mechanism to TALEs (Gilbert et al.,
2013; Maeder et al., 2013; Perez-Pinera et al., 2013; Qi et al., 2013).
As CRISPR-Cas9 target specificity is based on guide RNAs rather
than a modular protein domain, the generation of these ‘designer’
TFs is faster than the assembly of TALEs (Gaj et al., 2013).
However, a recent comparison between CRISPR-Cas9 and TALEs
Fig. 7. PU.1 expression is induced during the EHT
in vivo. (A) Fli1, PU.1 and Myb single-cell RT-qPCR
gene expression data from Swiers et al. (2013) in the
AGM region and vitelline and umbilical artery (AGM
+VUA) for VEcad+ cell populations from E10.5
embryos carrying a Runx1+23kb-GFP enhancer
reporter. Gene expression levels are displayed as a
heatmap of ΔCt relative to housekeeping genes (Ubc
and Atp5a1). (B) Genotype schematics and flow
cytometry plots displaying VEcad versus PU.1-YFP
expression for the Ter119− (Ly76−) cell population
from the AGM+VUA of E10.5 WT (left) and
homozygous PU.1-YFP transgenic (right) embryos.
Data were collected from pooled embryos and are
representative of two E10-10.5 embryo litters.
(C) Flow cytometry plots displaying CD41 versus
CD45 expression for the populations within the
VEcad/PU.1-YFP gates in B for the homozygous
PU.1-YFP transgenic embryos.
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suggested higher targeting specificity for the latter (Fu et al., 2013;
Mali et al., 2013).
The majority of previous research on PU.1 has concerned its role
in adult haematopoiesis, where high PU.1 levels promote terminal
myeloid differentiation, and reduced PU.1 expression results in
proliferation [reviewed by Mak et al. (2011)], consistent with our
CFU data. A novel link between PU.1 levels and the cell cycle has
been described recently, in which PU.1, by regulating cell cycle
lengthening, determines PU.1 protein accumulation within the cell,
effecting lympho-myeloid cell fate decisions (Kueh et al., 2013).
Our data additionally highlight the importance of tightly regulated
PU.1 expression for early haematopoiesis to occur. Moreover, since
our TALEs target conserved DNA sequences within cis-regulatory
elements, these tools can be directly applied to manipulate human
haematopoiesis.
PU.1 has recently been shown to inhibit proliferation by directly
controlling cell cycle regulators (Staber et al., 2013), which is
consistent with our observed loss of haematopoietic colonies
after TALE-VP64-mediated PU.1 upregulation and increase in
haematopoietic colonies after TALE-KRAB-mediated PU.1
repression. Our gene selection for the single-cell expression
analysis was focused on TF networks controlling early
haematopoietic development, and it is likely that genes other
than those assayed contribute to the phenotypic changes caused by
PU.1 expression perturbations, and this might well include cell
cycle regulators. It is worth highlighting that the TALE-mediated
perturbations caused consistent gene expression changes in
single cells, suggesting that PU.1 operates within a tightly
interconnected haematopoietic TF network.
In adult haematopoiesis, PU.1-14kb is a known target of Runx1
(Huang et al., 2008), a TF crucial for definitive haematopoiesis
(Okuda et al., 1996;Wang et al., 1996).We now report that thePU.1-
14kb element is active in vivo in mid-gestation AGM endothelium
and blood clusters, where definitive HSPCs arise, and PU.1 is
expressed in a subset of these haematopoietic precursors. Runx1 has
been shown to initiate chromatin unfolding at PU.1-14kb early
during haematopoietic specification (Hoogenkamp et al., 2009).
Such enhancer priming is likely to be important for efficient TALE-
VP64-mediated induction of expression. Although Hoogenkamp
et al. were unable to determine the frequency of such priming events
within the precursor population, our data would be consistent with a
model whereby the majority of VEcad+ cells contain primed PU.1-
14kb enhancers owing to the high efficiency of TALE-mediated
PU.1 expression activation in this cell type. Enhancer primingmight
also contribute to the low-level expression of PU.1 prior to
haematopoietic commitment, with more robust expression seen
later as haematopoietic TF network circuitry is reinforced. Such low-
level expression might be analogous to the transcriptional noise of
lineage regulators previously seen in adult haematopoietic
progenitor cells (Pina et al., 2012).
In summary, we have validated the use of TALEs targeting
conserved cis-regulatory elements as an efficient, multifaceted tool
to modulate endogenous gene expression and study TF regulatory
network perturbations in single cells, and in doing so we have
uncovered a role for PU.1 in haematopoietic specification.
MATERIALS AND METHODS
TALE design and assembly
TALE sequences were designed to 20 bp regions within the Scl+40kb and
PU.1-14kb elements that were conserved between human and mouse, and
were unique within both genomes by BlastN and Blat (Altschul et al., 1990;
Kent, 2002). TALEs were assembled and cloned into piggyBac (PB) as
described previously (Gao et al., 2013). For ChIP experiments, an HA-
tagged TALE-VP64 was used, as described previously (Gao et al., 2013).
Cell culture and transfection
K562 (Lozzio et al., 1981) and 416B (Dexter et al., 1979) cells were cultured
and electroporated as described previously (Knezevic et al., 2011;Moignard
et al., 2013), as in Fig. 1D. TALE expression was induced by addition of
2 μg/ml dox (Sigma) for 48 h andmCherry+ andmCherry–K562/416B cells
were sorted using a BD Influx (BD Biosciences). Ainv18 ESCs (Kyba et al.,
2002) were cultured as described previously (Ismailoglu et al., 2008) and
transfected by nucleofection (Lonza). OP9 stromal cells were cultured as
described previously (Nakano et al., 1994).
ESC differentiation and haematopoietic colony forming assays
ESCs were differentiated essentially as described previously (Wilkinson
et al., 2013), and treated as described in Fig. 2A and Fig. 3A. 100,000 day 6
EB cells were plated in triplicate in 1.1 ml M3434 Methocult (Stem Cell
Technologies). For OP9 co-culture colony forming assays, 100,000 day 6
EB cells were plated on confluent OP9 in MEMα supplemented with 10%
FCS for 24 h before the medium was replaced with M3434 Methocult.
Definitive haematopoietic colonies were counted after 10-12 days (see
supplementary material Fig. S2A for representative images of these colonies
and counting criteria).
Flow cytometry of EBs
Dissociated EB cells were stained with combinations of the antibodies listed
in supplementary material Table S3. Annexin V-APC (BD Biosciences,
550474) antibody and DAPI were used to assess cell apoptosis according to
the manufacturers’ instructions. Surface marker and mCherry expression
data were collected using a five-laser LSRFortessa (BD Biosciences) and
analysed using FlowJo software.
OP9 co-culture assays
MACS (Miltenyi) sorted Flk1+ cells from day 4 EBs (over 95% purity) were
cultured on confluent OP9s in MEMα supplemented with 10% FCS.
Mesodermal colonies were allowed to form for 36 h before dox was added.
Haematopoietic cells were not seen before this time point. After 48 h, cells
were fixed in 2% PFA overnight, blocked, stained with purified CD41
antibody (BD Biosciences, 553847, MWReg30), visualised by DAB
staining, and mesodermal colonies containing (at least two) small rounded
budding CD41+ haematopoietic cells were scored. Specific staining was
confirmed using an isotype control antibody. VEcad+ cells from day 6 EBs
were sorted using a BD Influx and plated on confluent OP9s, and cultured
for 4 days in MEMα supplemented with 10% FCS. After 4 days, cells were
fixed and stained as above using purified CD31 antibody (BD Biosciences,
553370, MEC13.3), and endothelial sheet colonies were scored.
RNA extraction and RT-qPCR
RT-qPCR was undertaken as described previously (Wilson et al., 2010a)
using the primers listed in supplementary material Table S4. All gene
expression values are normalised to ACTB/Actb.
Single-cell gene expression and data analysis
Single-cell sorting and gene expression analysis were undertaken as
previously described (Moignard et al., 2013) using a BD Influx and TaqMan
assays (see supplementary material Table S5). Partial correlation analysis, as
described elsewhere (Bailey, 1995), was applied to the normalised TF gene
expression data using Spearman correlation. Correlation values and
associated P-values are displayed in supplementary material Tables S1
and S2, respectively. Interactions where P<0.0001 are displayed as edges in
Fig. 6.
ChIP
mCherry+ 416B cells were sorted by FACS (24 h after dox addition), then
expanded without dox before HA-T-VP64 expression was induced for 48 h
and cells crosslinked using 1% formaldehyde (Sigma). ChIP-qPCR and
ChIP-seq were performed and analysed essentially as described previously
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(Wilson et al., 2010b) using anti-HA (Sigma, H6908) and anti-H3K27Ac
(Abcam, ab4729) antibodies, and the ChIP-qPCR primers listed in
supplementary material Table S6. ChIP-seq data are available at GEO
with accession number GSE61189.
Transient transgenic embryo generation
Promoter and enhancer reporter pGlac constructs were cloned as described
previously (Wilson et al., 2009) using the primers listed in supplementary
material Table S7. E11.5 transient transgenic embryos were generated by
Cyagen Biosciences (Guangzhou, China) and analysed as described (Ogilvy
et al., 2007).
PU.1-YFP embryo generation and analysis
Mice were housed with free access to food and water. All procedures were in
compliance with United Kingdom Home Office regulations and approved
by the Local Ethical Review Committee and the Home Office. Timed
matings were set up overnight between wild-type (CBA×C57BL/6)/F1 male
and female and homozygous PU.1-YFP male and female mice (Kirstetter
et al., 2006). Dissection and flow cytometry analysis were undertaken as
described previously (Swiers et al., 2013).
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Figure S1, related to Figure 1:
(A) Effect of expressing HA-TALE-VP64 targeting the Scl+40kb (HA-T-VP64-Scl+40) for 48 hr in mouse 416B on histone 3 lysine 27 
acetylation (H3K27Ac; relative to IgG enrichment) at the Scl+40kb, Scl promoter (prom), Map17 prom and a control region on chromo-
some 1 (chr1 control). HA-T-VP64-Scl+40 expressed for 48 hr by addition of doxycycline (+dox; pink bars). Untransfected 416B used 
as control (green bars). Error bars are standard deviation of technical triplicates from one biological experiment.
(B) Effect of expressing HA-TALE-VP64 targeting the PU.1-14kb (HA-T-VP64-PU.1-14) in mouse 416B on histone 3 lysine 27 acetyl-
ation (H3K27Ac) ChIP-qPCR enrichment (relative to IgG enrichment) at the PU.1-14kb, PU.1 prom, Slc39a13 prom and Chr1 control 
region. HA-T-VP64-PU.1-14 expressed for 48 hr by addition of dox (+dox; red bars). Untransfected 416B used as control (blue bars). 
Error bars are standard deviation of technical triplicates from one biological experiment.
(C) Effect of expressing TALE-VP64 targeting the Scl+40kb (T-VP64-Scl+40) in mouse Ainv18 ES cells on Scl and Map17 gene ex-
pression, normalised to ActB. T-VP64-Scl+40 expressed for 48 hr by addition of dox and gene expression in +dox cells (green bars) 
determined relative to –dox control cells (pink bars). Error bars are standard deviation of technical triplicates from one biological ex-
periment. 
(D) Effect of expressing TALE-VP64 targeting the PU.1-14kb (T-VP64-PU.1-14) in mouse Ainv18 ES cells on PU.1 and Slc39a13 
gene expression, normalised to ActB. T-VP64-PU.1-14 expressed for 48 hr by addition of dox and gene expression in +dox  cells (blue 
bars) determined relative to –dox control cells (red bars). Error bars are standard deviation of technical triplicates from one biological 
experiment. 
(E) UCSC Genome Browser screen shot of RefSeq annotated genes within a ~300kb genomic window surrounding the Scl+40kb en-
hancer (highlighted in green).
(F) UCSC Genome Browser screen shot of RefSeq annotated genes within a ~150kb genomic winder surrounding the PU.1-14kb en-
hancer (highlighted in green).
(G) Effect of expressing T-VP64-Scl+40 in human K562 (top), mouse 416B and mouse Ainv18 ES cells on Cmpk1, Stil, Cyp4x1 and 
Cyp4a29-ps gene expression, normalised to ACTB/ActB. T-VP64-Scl+40 expressed for 48 hr by addition of dox and gene expression 
in +dox/mCherry+ cells (green bars) determined relative to –dox/mCherry- control cells (pink bars). Error bars are standard deviation of 
technical triplicates from one biological experiment. Not detected; N.D
(H) Effect of expressing T-VP64-PU.1-14 in human K562 (top), mouse 416B and mouse Ainv18 ES cells on Rapsn, Psmc3, Mybpc3 
and Madd gene expression, normalised to ACTB/ActB. T-VP64-PU.1-14 expressed for 48 hr by addition of dox and gene expression 
in +dox/mCherry+ cells (blue bars) determined relative to –dox/mCherry- control cells (red bars). Error bars are standard deviation of 
technical triplicates. Not detected; N.D
(I) UCSC Genome Browser screenshot of HA antibody ChIP-Seq enrichment in a ~15Mb window surrounding the PU.1-14kb element 
in wild type (above) and T-VP64-PU.1-14 expressing (below) 416B cells.
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(-)dox (+)dox p value
Flk1+ 164633±80581 47503±41865 <0.01
CD41+ 157083±135844 143550±115053 N.S
CD41+VEcad+ 2213±2299 12852±11881 <0.05
CD41+cKit+ 11445±8974 1945±1503 <0.05
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Figure S2, related to Figure 2:
(A) Representative images of haematopoietic colonies scored in methylcellulose CFU assays in Figures 2C and S2B. Red coloured 
erythroid colonies of at least ~30 small cells dispersed within small clusters with tight cell-cell junctions were scored as burst forming 
unit erythroid (BFUe). Colonies of at least ~50 small round bright cells (often tightly packed with grey centre) were scored as colony 
forming unit-granulocyte (CFU-G). Large colonies of over ~200 cells containing both granulocytes (as described above) and macro-
phages (large round cells, less bright than granulocytes and often more dispersed) were scored as colony forming unit-granulocyte 
macrophage (CFU-GM). Large colonies of over ~200 cells, densely packed, including red erythroid cells (similar to those described 
above) as well as at least two other lineages (usually granulocytes and macrophages described above) or megakaryocytes were scored 
as colony forming unit-mix (CFU-Mix).
(B) Representative haematopoietic colonies numbers from 1 x 105 day 6 EB cells derived from mouse ES cells inducible expressing a 
non-functional TALE-VP64 (due to mutations within the DNA binding domain), previously generated (Gao et al., 2013). As in Figure 
2C, dox added to EBs day 4 to induce TALE-VP64 expression. Colonies grown in methylcellulose supplemented with SCF, IL-3, IL-6 
and Epo. Error bars are standard deviation of technical triplicates. No statistically significant changes in CFU numbers were seen from 
three biological triplicates, as determined by the student t test.
(C) Flow cytometry plots of day 6 EB cells showing (from top to bottom) Flk1 vs. CD41, VE cadherin (VEcad) vs. CD41, cKit vs. 
CD41, CD45 vs. CD41). Representative staining patterns for a T-VP64-Scl+40 expressing mouse ES cell line, both uninduced (-dox) 
and induced (from day 4; +dox). Distribution of cells within quadrant/gates shown as percentages.
(D) Total number (light grey bars), frequency of apoptotic (Annexin V+ DAPI-; dark grey bars) and frequency of dead (Annexin V+ 
DAPI+; black bars) T-VP64-Scl+40, T-VP64-PU.1-14 and T-KRAB-PU.1-14 expressing EB day 6 cells (+dox from day 4) relative to 
–dox controls. Error bars are standard deviation of three biological replicates. No statistically significant changes were seen from three 
biological triplicates, as determined by the student t test.
(E) Flow cytometry plots of day 6 EB cells showing Flk1 vs. CD41 (top) and CD41 vs. CD45 (bottom). Representative staining patterns 
for TALE-VP64 (left) and TALE-KRAB (right) targeting PU.1-14kb clones, both uninduced (-dox) and induced (from day 4; +dox). 
Distribution of cells within quadrant/gates shown as percentages.
(F) Table displaying absolute cells numbers for cells populations identified by flow cytometry in Figure 2D ± standard deviation from 
three biological replicates, and p values (using the student t test). N.S; not significant.
(G) Representative image of day 4 EB Flk1+-derived colony containing haematopoietic (round, budding) CD41+ (stained black) cells 
scored in Figure 2E. Colonies containing endothelial cells that stained weakly CD41+ were not scored unless haematopoietic cells were 
also present.
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VEcad+ mC- (136 cells) VEcad+ mC+ (147 cells)
Figure S3, related to Figure 3:
Density plots of gene expression in day 6 EB VEcad+ mCherry- (136 WT Ainv18; in cyan) and VEcad+ mCherry+ (147 Ainv18 express-
ing T-VP64-PU.1-14; in red) for all 48 genes analysed. The density indicates the fraction of cells at each expression level, relative to 
housekeeping genes (Polr2a and Ubc). Cells with non-detected gene expression set to -12.
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Figure S4, related to Figure 4:
Density plots of gene expression in day 6 EB CD41+cKithi mCherry- (141 WT Ainv18; in orange) and CD41+cKithi mCherry+ (142 
Ainv18 expressing T-KRAB-PU.1-14; in purple) for all 48 genes analysed. The density indicates the fraction of cells at each expression 
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Figure S5, related to Figure 4: 
Representative images of endothelial colony assays from day 6 EB VEcad+ cells from T-VP64-PU.1-14 or T-KRAB-PU.1-14 ES cell 





























WT and PU.1-YFP transgenic embryos
E10.5 AGM/VUA region
Figure S6, related to Figure 7:
Alternative analysis of flow cytometry data from Figure 6B,C, plots displaying PU.1-YFP expression vs. FSC for VEcad+ Ter119- 
CD41- CD45- (left), VEcad+ Ter119- CD41+ CD45- (middle) and VEcad+ Ter119- CD41+ CD45+ (right) populations from the AG-
M+VUA region of pooled E10.5 WT (above) and PU.1-YFP (below) embryos.
Supplementary Table 1: Partial Correlation Analysis
Download Table S1
Supplementary Table 2: Partial Correlation Analysis
Download Table S2
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Supplementary Table 3: Flow Cytometry Antibodies
Antibody Supplier Cat. Number Clone ID Reactivity
CD16/32 (Fc block) BD 553142 2.4G2 Mouse
CD41-PE-Cy7 Biolegend 25-0411-82 eBioMWReg30 Mouse
CD41-APC eBioscience 17-0411 MWReg30 Mouse
CD45-APC Biolegend 103112 30-F11 Mouse
Flk1-APC BD 560070 Avas 12a1 Mouse
Flk1-PE BD 561052 Avas 12a1 Mouse
VEcad-PE-Cy7 Biolegend 92055 VECD1 Mouse
cKit-APC BD 553356 2B8 Mouse
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Supplementary Table 4: RT-qPCR primers 
Primer name Sequence 
Human ACTB forward AGAGCTACGAGCTGCCTGAC 
Human ACTB reverse AGCACTGTGTTGGCGTACAG 
Human SCL/TAL1 forward TTCCCTATGTTCACCACCAA 
Human SCL/TAL1 reverse AAGATACGCCGCACAACTTT 
Human MAP17 forward TGCCTATGAGAATGTGCCG 
Human MAP17 reverse TGGACATCCATCCCATGTGC 
Human PU.1/SPI-1 forward CGGCTGGATGTTACAGGCGTG 
Human PU.1/SPI-1 reverse TCGTGCGTTTGGCGTTGG 
Human SLC39A13 forward TTCCCCTAGAGATGGGGACC 
Human SLC39A13 reverse GGCAGCAGATGCAGAAACAC 
Human PSMC3 forward ACAGACGTACTTCCTTCC 
Human PSMC3 reverse CCAATGAACATCTGCACCAG 
Human RAPSN forward GTACGACTCCGCCATGAGCA 
Human RAPSN reverse ATGGCATCCAGAGCCTTGTCC 
Human MYBPC3 forward GCTCTTCCAGACCCATCTCG 
Human MYBPC3 reverse CAGCGGGATGACAGGAAACA 
Human MADD forward TAGTGATCGTAGGGGCCAGG 
Human MADD reverse GCAGGGGAAACTCAGTGTGA 
Human STIL forward ATGCACATAACGTGGATCACG 
Human STIL reverse TCCATGCTCAAATCCACACC 
Human CMPK1 forward TCTCATGAAGCCGCTGGT 
Human CMPK1 reverse TCCTGCAGAAAGGTGTGTGT 
Human CYP4X1 forward TCAGGACACAAGCGTGGAGGTCTA 
Human CYP4X1 reverse TGCATAAGGATCATGGGTGCTGTT 
Human CYP4A29-PS forward CTGCTTTTCAAGGCAGCACA 
Human CYP4A29-PS forward CTGCAAGCAATGCCCAAAGA 
Mouse Actb forward TCCTGGCCTCACTGTCCAC 
Mouse Actb reverse GTCCGCCTAGAAGCACTTGC 
Mouse Scl/Tal1 forward CATGTTCACCAACAACAACCG 
Mouse Scl/Tal1 reverse GGTGTGAGGACCATCAGAAATCTC 
Mouse Map17 forward GTCCTTGTTGCAATCGTCTTC 
Mouse Map17 reverse GAGGAGTATCTGCCATCCATTC 
Mouse PU.1/Sfpi-1 forward AGAGCATACCAACGTCCAATG C 
Mouse PU.1/Sfpi-1 reverse GTGCGGAGAAATCCCAGTAGTG 
Mouse Slc39a13 forward TTGCTGGTCATTCCCCTGGA 
Mouse Slc39a13 reverse GTCCACCTAAGGCAAAGCTGA 
Mouse Psmc3 forward GACCGTGTGGGATGAAGCTG 
Mouse Psmc3 reverse CGCTGGACAATCTCTTCCGTG 
Mouse Rapsn forward ATATCGGGCCATGAGCCAGT 
Mouse Rapsn reverse TCACAACACTCCATGGCACTGC 
Mouse Mybpc3 forward TGAAGGGTCAGTCTCGGTAACC 
Mouse Mybpc3 reverse TCCTGTGGTCGCATCAGAAA 
Mouse Madd forward AAGAAACTGGGCATCCCTCG 
Mouse Madd reverse GAAGGGCACTGGACTTCTCC 
Mouse Stil forward GGTGATGATCAAGAGCCCGA 
Mouse Stil reverse ACCAGGTTCTTTGCTCTGCT 
Mouse Cmpk1 forward TCAGAAGCGCGTTGTATGCT 
Mouse Cmpk1 reverse AAAACGAACACGACCAACGG 
Mouse Cyp4x1 forward CCTGGACATAATAATGAAATGTGCTT 
Mouse Cyp4x1 reverse CTTCACGTAAGACTCATAGGTGCC 
Mouse Cyp4a29-ps forward CAGTGCACCATCTGGACCTC 
Mouse Cyp4a29-ps reverse GATTACGTAATAGTGGTCCCTCAGG 
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Supplementary Table 5: Taqman assays used for single cell gene expression 
















































VE cadherin Mm00486938_m1 
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Supplementary Table 6: ChIP-qPCR primers 
 
Primer name Sequence 
Scl promoter F CATGCGCACTCCAGCCTC 
Scl promoter R CACACACCGCCCAGAAGC 
Map17 promoter F ACAAGGTAGCACAGGACAGG 
Map17 promoter R TCCAAAACACCACCCCATCC 
Scl+40kb F CTCTTCCTTATCGCCAGCTC  
Sc+40kb R CAGCTGGTGCGTTATCAGTT 
PU.1 promoter F GGGCCATTGGCTTCCTTAGA 
PU.1 promoter R AATAGCTGTTCAGGCCCCAC 
Slc39a13 promoter F AGAGTAGGACGGAAGTGGGTA 
Slc39a13 promoter R CTGTTGATCCCGGTTCCCG 
PU.1-14kb F GCTGTTGGCGTTTTGCAAT 
PU.1-14kb R GGCCGGTGCCTGAGAAA 
Chr1 control CATAGATGAAGCTGCCACATAGGT 
Chr1 control GTGGGCAAGGACAAAGCATTA 
 
Development | Supplementary Material




PU.1prom_R taaaagcttGCTGAGCTCCAGGTTGGTC  
PU.1-14kb_F taaggatccGCTTGGGTGCTGGACTTAGA  
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